Filing Analysis
Neuraxis, Inc. announced the effective date of a stock option exchange and the granting of various Restricted Stock Units (RSUs) to key executives and independent directors. The filing also details new equity awards for the CFO and other officers vesting over three years.
🚩 Red Flags
- Significant equity dilution through the issuance of over 1.3 million RSUs and additional RSU grants to executives.
📋 Key Facts
- Stock Option Exchange became effective on July 24, 2026, converting 1,319,394 outstanding stock options into an equivalent amount of RSUs.
- Brian Carrico (CEO), Adrian Miranda (CMO), and Thomas Carrico (CRO) received RSUs totaling 591,972 units, vesting immediately.
- On August 13, 2026, the Company granted RSUs to the CEO, CFO, CMO, and CRO that vest in three equal annual installments over three years.
- Independent directors were granted 127,120 shares of common stock as one-time equity awards to align compensation with market levels.
Neuraxis, Inc. has declared a stock dividend for its Series B Preferred Stock for the second quarter of 2026. The dividend will be paid in common stock to holders of record as of July 21, 2026.
📋 Key Facts
- Dividend Type: Stock dividend on Series B Preferred Stock payable in Common Stock.
- Dividend Period: Accrued and unpaid dividends from April 1, 2026, through the record date.
- Conversion Rate: Based on a value of $2.38 per share for calculation purposes.
- Expected Issuance: Approximately 80,463 shares of Common Stock.
- Record Date: July 21, 2026; Payment Date: July 29, 2026.
- Fractional Shares: No fractional shares will be issued; cash in lieu of fractions will be paid based on the $2.38 rate.
Neuraxis, Inc. reported the results of its Annual Meeting of Stockholders held on June 10, 2026. The company successfully elected six directors, ratified its independent accounting firm, and approved amendments to its Omnibus Securities and Incentive Plan and its Employee Stock Purchase Plan.
📋 Key Facts
- Annual Meeting held on June 10, 2026, with a quorum representing approximately 73.51% of outstanding votes.
- Six director nominees were elected to one-year terms.
- Rosenberg Rich Baker Berman, P.A. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The 2022 Omnibus Securities and Incentive Plan was amended (specifically Section 5.1).
- The 2025 Employee Stock Purchase Plan (ESPP) was approved, with a modification to Section 5(c) increasing the ownership limitation for purchase rights from 5% to 10%.
Neuraxis, Inc. has amended its At-The-Market (ATM) offering agreement with Craig-Hallum Capital Group LLC to increase the maximum aggregate offering price from $6,270,000 to $11,500,000. The company reported selling 1,125,281 shares under the original agreement between August 2025 and April 2026.
🚩 Red Flags
- Significant potential for shareholder dilution as the offering size was nearly doubled.
- Ongoing reliance on equity sales to provide liquidity/capital.
📋 Key Facts
- ATM offering capacity increased by $5,230,000 to a new total of $11,500,000.
- 1,125,281 shares of common stock were sold under the agreement from August 29, 2025, through April 20, 2026.
- The sales agent for the offering is Craig-Hallum Capital Group LLC.
- The offering is conducted under an effective Registration Statement on Form S-3 (File No. 333-283798).
Neuraxis, Inc. announced preliminary unaudited financial results for Q1 2026, reporting a 77% increase in net sales to $1.6 million compared to the prior year. The company maintains a strong gross margin of approximately 87.5% but continues to operate at a loss.
🚩 Red Flags
- Operating loss of $1.7 million exceeds total quarterly revenue of $1.6 million.
- Based on the $1.7 million quarterly operating loss, the $7.1 million cash balance provides approximately four quarters of runway without additional funding or revenue scaling.
📋 Key Facts
- Preliminary net sales of approximately $1.6 million for the three months ended March 31, 2026, up from $0.9 million in the same period of 2025.
- Cash and cash equivalents were approximately $7.1 million as of March 31, 2026.
- Estimated gross profit of $1.4 million for Q1 2026.
- Estimated operating loss of $1.7 million for the quarter ended March 31, 2026.
- The company is an emerging growth company and is still finalizing its quarter-end financial close process.
Neuraxis, Inc. announced FDA 510(k) clearance for its PENFS technology to treat functional dyspepsia (FD) in patients aged 8 and older, expanding its indication to adults. Additionally, the company amended its At-The-Market (ATM) offering agreement with Craig-Hallum Capital Group LLC to increase the aggregate offering price from $3.3 million to $6.27 million.
🚩 Red Flags
- Increased capacity for equity dilution via the expanded $6.27M ATM offering.
📋 Key Facts
- FDA 510(k) clearance received for PENFS technology for functional dyspepsia (FD) and related nausea in patients aged 8+ years.
- FDA extrapolated pediatric clinical data to support use in the adult population.
- Amended At-The-Market (ATM) offering agreement with Craig-Hallum Capital Group LLC.
- Increased aggregate offering amount from $3,300,000 to $6,270,000.
- No shares were sold under the ATM agreement between August 29, 2025, and October 23, 2025.
Neuraxis, Inc. released preliminary unaudited financial results for the three and nine months ended September 30, 2025. The company reported significant operating losses despite a year-over-year increase in net sales.
🚩 Red Flags
- Significant operating loss of $2.1 million for a single quarter.
- Low cash position ($4.4M) relative to quarterly burn rate (implied by the operating loss).
- Preliminary estimates are unaudited and subject to material adjustments.
📋 Key Facts
- Preliminary cash and cash equivalents: ~$4.4 million as of Sept 30, 2025.
- Q3 2025 preliminary net sales: ~$0.8 million.
- Q3 2025 preliminary gross profits: ~$0.7 million.
- Q3 2025 preliminary operating loss: ~$2.1 million.
- 9-month 2025 preliminary net sales: ~$2.6 million (up from $1.9 million in the same period in 2024).
- The company is currently finalizing its quarter-end financial statement close process.
Neuraxis, Inc. entered into an At-The-Market (ATM) offering agreement with Craig-Hallum Capital Group LLC to sell up to $3.3 million in common stock. This allows the company to raise capital incrementally through various methods under its existing S-3 registration statement.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to fund immediate operational cash needs (liquidity management).
📋 Key Facts
- Entered into an At The Market Offering Agreement on August 29, 2025.
- Aggregate offering price of up to $3,300,000 in common stock.
- Sales Agent: Craig-Hallum Capital Group LLC.
- Commission rate: 3% of gross sales proceeds.
- Company will reimburse Sales Agent for legal fees up to $50,000 plus $5,000 per due diligence update.
Neuraxis, Inc. has entered into a termination agreement with Masimo Corporation to end their 2020 license and collaboration agreement for the NSS-2 Bridge device. As part of this termination, Neuraxis will pay Masimo $200,000 in two installments through mid-2026 and will lose all future licensing revenue from this product line.
🚩 Red Flags
- Loss of recurring revenue stream: The company will no longer receive licensing payments from the NSS-2 Bridge device/Masimo Bridge.
- Cash outflow: A $200,000 cash obligation has been triggered to terminate the agreement.
📋 Key Facts
- Termination date: July 1, 2025.
- Company to pay Masimo Corporation $200,000 in cash (two equal installments due Dec 31, 2025, and June 30, 2026).
- The agreement terminates the exclusive, royalty-free license for patents/trademarks related to the NSS-2 Bridge device.
- Neuraxis will no longer receive any licensing payments or revenue from the Masimo Bridge product line.
- Board adopted a new 2025 Employee Stock Purchase Plan (ESPP) on July 1, 2025.
Neuraxis, Inc. held its annual meeting of stockholders on May 29, 2025, where several key matters were voted upon. The results included the election of six directors and the ratification of the company's independent auditor.
🚩 Red Flags
- The approval of the issuance of 20% or more of common stock via Series B conversion can lead to significant dilution for existing common shareholders.
📋 Key Facts
- Annual Meeting held on May 29, 2025, in Carmel, Indiana.
- Quorum was established with 59.22% of outstanding votes represented (5,660,885 total votes).
- Six directors were elected: Brian Carrico, Dr. Christopher R Brown, Bradley Mitch Watkins, Beth Keyser, Kristen Ferge, and Dr. Gilad Aharon.
- Rosenberg Rich Baker Berman, P.A. was ratified as the independent registered public accounting firm for fiscal year 2025.
- Shareholders approved a proposal regarding the issuance of 20% or more of outstanding Common Stock upon conversion of Series B Convertible Preferred Stock.
Neuraxis, Inc. filed an 8-K to announce the posting of a new investor presentation on its website. The presentation outlines the company's strategy, performance, and future objectives.
📋 Key Facts
- Investor Presentation posted on May 23, 2025.
- Presentation covers company strategy, performance, and future objectives.
- The information is provided under Item 7.01 (Regulation FD Disclosure).
Neuraxis, Inc. entered into a securities purchase agreement to sell 1,538,461 shares of common stock at $3.25 per share to institutional investors. The offering is expected to raise approximately $5.0 million in gross proceeds for working capital and general corporate purposes.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of new common stock.
📋 Key Facts
- Offering size: 1,538,461 shares of common stock.
- Price per share: $3.25.
- Expected gross proceeds: Approximately $5.0 million.
- Placement Agent: Craig-Hallum Capital Group LLC.
- Use of proceeds: Working capital and general corporate purposes.
- Closing date: Expected on or about May 22, 2025.
Neuraxis, Inc. has entered into a settlement agreement to resolve long-standing lawsuits from multiple parties, involving a $750,000 liability. Additionally, the company reported significant cash inflows from warrant exercises and Series B conversions.
🚩 Red Flags
- Material legal liability ($750k) being paid out over a long duration (starting Jan 2026).
- Significant dilution through the issuance of nearly 772,000 new common shares via warrants and conversions.
📋 Key Facts
- Settlement amount of $750,000 agreed upon on May 15, 2025.
- Settlement payable in 12 equal monthly installments starting January 2026.
- Received approximately $1 million in proceeds from warrant exercises between May 20-21, 2025.
- Issued 430,580 shares of Common Stock via warrant exercises.
- Three Series B Preferred Stock holders converted to receive 342,016 shares of Common Stock.
Neuraxis, Inc. issued a press release announcing preliminary unaudited revenue estimates for the three and twelve months ended December 31, 2024.
🚩 Red Flags
- Preliminary data is unaudited and subject to change upon completion of the annual audit.
📋 Key Facts
- Report date: January 8, 2025
- The company released preliminary unaudited information regarding estimated revenues for Q4 and FY2024.
- Financial statements are subject to ongoing audit and normal financial close procedures.
- Information is provided under Item 2.02 of Form 8-K.
Neuraxis, Inc. announced the appointment of Dr. Gil Aharon to its Board of Directors, effective January 1, 2025. This follows a $5 million Series B Convertible Preferred Stock issuance involving three related investors.
🚩 Red Flags
- Related-party involvement: The new director is a co-founder of an advisor to one of the primary investors in a recent $5 million financing.
- Potential dilution: Issuance of 2.1M shares of Series B Convertible Preferred Stock.
📋 Key Facts
- The company entered into securities purchase agreements (SPAs) on November 9, 2024.
- Issuance of 2,100,840 shares of Series B Convertible Preferred Stock for approximately $5 million.
- Dr. Gil Aharon appointed to the Board effective January 1, 2025.
- Dr. Aharon is a co-founder of Rosalind Advisors, Inc., which serves as an advisor to one of the three Investors in the transaction.
- Dr. Aharon personally purchased 105,042 shares for approximately $250,000.
Neuraxis, Inc. filed an amendment to its Certificate of Designation regarding Series B Preferred Stock. The amendment increases authorized Series B shares and extends dividend rights while adjusting conversion terms.
🚩 Red Flags
- Modification of preferred stock terms often indicates the company is negotiating with existing major investors to prevent default or provide liquidity.
- Extension of dividend rights suggests the company may be struggling to meet upcoming cash obligations related to these dividends.
- Changes to conversion prices and voting rights can lead to significant dilution for common shareholders.
📋 Key Facts
- Filed Amendment No. 1 to Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock on November 15, 2024.
- Increased authorized Series B Preferred Stock from 4,000,000 to 5,000,000 shares.
- Extended the 8.5% per annum dividend right by 18 months (from June 30, 2025, to December 31, 2026).
- Amended voting rights for Series B holders based on a conversion price of $3.80.
Neuraxis, Inc. entered into securities purchase agreements to issue 2,100,840 shares of Series B Convertible Preferred Stock for approximately $5 million. The transaction includes significant concessions to investors, including extended dividend rights and punitive liquidated damages in registration rights agreements.
🚩 Red Flags
- Convertible Preferred Stock: Ranks senior to common stock and is convertible at any time into common stock, creating significant dilution risk.
- Punitive Registration Rights: The inclusion of liquidated damages (up to 6%) and high interest rates (18% per annum) for registration delays is highly unfavorable to existing shareholders.
- Dividend Concessions: Extending dividend rights by 1.5 years suggests the company had significant leverage issues during negotiations.
📋 Key Facts
- Total transaction value: Approximately $5 million.
- Securities issued: 2,100,840 shares of Series B Convertible Preferred Stock.
- Stated value of Series B Preferred Stock: $2.38 per share.
- Dividend extension: Right to receive dividends extended from June 30, 2025, to December 31, 2026.
- Authorized shares increase: Amendment to Certificate of Designation to increase Series B authorized shares from 4M to 5M.
- Registration rights penalties: Liquidated damages of 1% per month (up to 6%) for failure to meet registration deadlines, plus 18% annual interest on unpaid damages.
Neuraxis, Inc. announced its financial results for the third quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2024
- Announcement date: November 12, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial performance.
Neuraxis, Inc. has significantly reduced its total investment commitment from Flagstaff International from $5 million down to $1.8 million via a fourth amendment. Additionally, the company entered into new securities purchase agreements with several investors for $145,000 in Series B Preferred Stock.
🚩 Red Flags
- Significant reduction in planned capital infusion (from $5M down to $1.8M) suggests liquidity or funding difficulties.
- Heavy reliance on convertible preferred stock which may lead to significant dilution for common shareholders upon conversion.
- Series B Preferred Stock has a liquidation preference senior to Common Stock.
- The rapid succession of amendments and small-scale new offerings indicates potential cash runway constraints.
📋 Key Facts
- Fourth Amendment to Flagstaff SPA (Oct 12, 2024) reduces total investment from $5M to $1.8M.
- Flagstaff International previously paid $800,000 and received 336,132 shares of Series B Preferred Stock.
- Remaining Flagstaff obligation: $1,000,000 ($500k due by Nov 27, 2024; $500k due by Dec 31, 2024).
- New SPAs entered Oct 16, 2024: Issuance of 60,924 shares of Series B Preferred Stock for ~$145,000.
- Series B Preferred Stock converts to common stock without further consideration and ranks senior to Common Stock.
- Registration Rights Agreements were signed alongside the new SPAs.
Neuraxis, Inc. has completed the automatic conversion of approximately $4.94 million in convertible promissory notes into 2,073,524 shares of Series B Preferred Stock following stockholder approval on August 15, 2024.
🚩 Red Flags
- Significant dilution risk: The conversion of nearly $5M in debt into over 2 million preferred shares will result in substantial dilution for existing common shareholders.
- Complex capital structure: Multiple rounds of convertible promissory notes (First, Second, and Third Series B) indicate a heavy reliance on debt-to-equity financing to sustain operations.
- Seniority risk: The newly issued Series B Preferred Stock ranks senior to Common Stock in liquidation/dissolution.
📋 Key Facts
- Stockholder approval for the creation of Series B Preferred Stock was obtained on August 15, 2024.
- The conversion involved $4,935,001.90 in principal owed under various 'Preferred Stock Notes'.
- A total of 2,073,524 shares of Series B Preferred Stock were issued on September 9, 2024.
- The conversion price for the notes was set at $2.38 per share.
- Flagstaff International, LLC is a primary participant in these financing rounds, having lent $800,000 to date through various agreements.
Neuraxis, Inc. held its annual meeting of stockholders on August 15, 2024, where several key proposals were approved, including the election of directors and amendments to corporate governance documents.
🚩 Red Flags
- Approval of 'blank check' preferred stock can facilitate rapid issuance of new equity without immediate shareholder vote on specific terms.
- Approval of the conversion of Series B Convertible Preferred Stock/notes that could result in 20% or more dilution to existing common shareholders.
📋 Key Facts
- Annual Meeting held on August 15, 2024, with a quorum representing approximately 65.61% of outstanding votes.
- Five nominees for director (Brian Carrico, Dr. Christopher R Brown, Bradley Mitch Watkins, Beth Keyser, and Kristen Ferge) were elected to one-year terms.
- Ratification of Rosenberg Rich Baker Berman, P.A. as the independent registered public accounting firm for fiscal year 2024 was approved.
- Shareholders approved an amendment to authorize 'blank check' preferred stock.
- Shareholders approved a proposal regarding the issuance of 20% or more of outstanding Common Stock upon conversion of Series B Convertible Preferred Stock or certain convertible promissory notes.
- The company amended its 2022 Omnibus Securities and Incentive Plan.
Neuraxis, Inc. announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024
- Filing date: August 9, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Neuraxis, Inc. announced the issuance of unrestricted stock awards to three non-employee directors as compensation for services rendered through March 31, 2024. The company also established a recurring quarterly equity compensation arrangement for these directors.
🚩 Red Flags
- Equity compensation to directors is a standard practice but represents a continuous dilution mechanism via the 2022 Omnibus Securities and Incentive Plan.
📋 Key Facts
- Three non-employee directors (Kristin Ferge, Beth Keyser, and Bradley Mitch Watkins) were granted common stock awards on June 28, 2024.
- Shares were issued based on the closing price of $2.78 per share as of June 28, 2024.
- The grants cover services provided through March 31, 2024.
- Directors will receive quarterly stock awards valued at $12,500 each, totaling $50,000 in annual equity compensation per director.
Neuraxis, Inc. entered into a new securities purchase agreement on May 21, 2024, to issue convertible promissory notes totaling approximately $3 million to three institutional investors. The financing includes significant changes to previous Series B Preferred Stock terms and introduces potential dilution through conversion rights.
🚩 Red Flags
- High potential for dilution due to convertible notes at a fixed price of $2.38 per share.
- The company has not yet sought the required Stockholder Approval for Series B Preferred Stock, creating uncertainty around conversion mechanics.
- Existence of 'down-round' protection/anti-dilution features in existing 2023 Warrants (Section 3(b)) which were recently amended to prevent further share increases.
- The company is relying on multiple rounds of convertible debt (Flagstaff, nine accredited investors, and now three new institutional investors) to fund operations.
📋 Key Facts
- New issuance of convertible promissory notes for an aggregate purchase price of ~$3 million.
- Notes bear an 8.5% annual interest rate, payable in cash or common stock at $2.38 per share.
- Maturity date is June 21, 2025, unless demand is made after March 21, 2025, if stockholder approval for Series B is not obtained.
- If Stockholder Approval is not obtained by August 15, 2024, investors have the right to convert notes into common stock at $2.38 per share.
- Series B Preferred Stock terms were amended: number of shares increased from 1.5M to 4M; stated value changed from $1.00 to $2.38; dividend/liquidation rights expire June 30, 2025.
- Investors obtained Registration Rights Agreements (S-1 or S-3) and piggyback registration rights.
Neuraxis, Inc. announced the immediate termination of its Chief Operating Officer, Dan Clarence, effective April 10, 2024. The company will provide severance via salary continuation and COBRA coverage through October 2025.
🚩 Red Flags
- Immediate termination of a C-suite officer (COO) can sometimes signal internal friction or strategic shifts.
- Severance package includes extended healthcare coverage (COBRA) for an additional year beyond salary continuation.
📋 Key Facts
- Dan Clarence terminated as COO effective April 10, 2024.
- Severance includes salary continuation of $275,000 per year through October 10, 2024.
- Company will pay monthly COBRA premiums for health coverage through October 10, 2025.
Neuraxis, Inc. has determined that its previously issued unaudited financial statements for the three and nine months ended September 30, 2023, should no longer be relied upon due to a material accounting error regarding warrant liability classification. The company also expects to disclose a material weakness in its internal controls over financial reporting in its upcoming Form 10-K.
🚩 Red Flags
- Restatement of previously issued financial statements (Item 4.02).
- Identification of a material weakness in internal controls over financial reporting.
- Material error involving a significant dollar amount ($3.7M) relative to the company's scale.
📋 Key Facts
- The Board concluded that unaudited financial statements for periods ended September 30, 2023, should be restated due to material accounting errors.
- The error involved a $3,721,007 reduction of warrant liability that was incorrectly recorded as an extinguishment of debt charge instead of a reclassification to additional paid in capital.
- This resulted in a $3,721,007 understatement of net loss on the Statement of Operations and an equivalent understatement of additional paid in capital on the Balance Sheet.
- The error did not affect the company's cash position as of September 30, 2023.
- Management identified a material weakness in internal controls over financial reporting related to this matter.
Neuraxis, Inc. has amended its existing securities purchase agreement with Flagstaff International, LLC to increase the total investment from $3 million to $5 million and shift the instrument from Series B Preferred Stock to a convertible promissory note.
🚩 Red Flags
- Frequent amendments to financing agreements (three amendments mentioned) suggest unstable or evolving capital terms.
- Shift from equity issuance (Preferred Stock) to debt (Convertible Promissory Note) often indicates increased pressure on cash flow and potential dilution risk for common shareholders.
- The company has only received $400,000 of the total committed funds, indicating significant reliance on future installments that are subject to stockholder approval.
📋 Key Facts
- Total investment increased from $3 million to $5 million via Third Amendment dated March 22, 2024.
- The instrument has been changed from Series B Preferred Stock to a convertible promissory note.
- The $5 million is to be paid in 15 monthly installments of differing amounts.
- As of the filing date (March 28, 2024), the company has received $400,000 of the funding.
- Upon stockholder approval and filing of Certificate of Designation, the Note will convert into 2,100,841 shares of Series B Preferred Stock.
Neuraxis, Inc. announced the appointment of Kristin Ferge to its Board of Directors and as Chair of the Audit Committee. Ms. Ferge is an audit committee financial expert with extensive experience in senior living corporate finance.
📋 Key Facts
- Kristin Ferge appointed to the Board effective March 7, 2024.
- Ms. Ferge appointed as Chairman of the Audit Committee; designated as a 'financial expert' under Regulation S-K.
- Annual compensation for Ms. Ferge includes $60,000 in cash and $50,000 in common stock.
- Ms. Ferge previously served as EVP, Treasurer, and Chief Accounting Officer at Brookdale Senior Living Inc.
- Ms. Ferge is a CPA and former auditor with KPMG.
Neuraxis, Inc. has entered into multiple securities purchase agreements involving convertible promissory notes and an amendment to a prior $3 million Series B Preferred Stock agreement with Flagstaff International. The company is raising capital through debt instruments that convert into preferred stock or common stock, indicating significant near-term dilution.
🚩 Red Flags
- High potential for dilution due to multiple convertible promissory notes and Series B Preferred Stock conversion rights.
- Use of 'convertible debt' as a primary funding mechanism is common in distressed or cash-strapped micro-caps.
- The company has not yet sought stockholder approval required for the full $3 million Series B issuance, creating uncertainty regarding the capital structure.
- Registration Rights Agreements (RRAs) were signed, which typically lead to significant S-1/S-3 filings and subsequent selling pressure from investors.
📋 Key Facts
- Entered into SPAs on Feb 9 and Feb 14, 2024, for convertible promissory notes totaling $457,000 at an 8.5% interest rate.
- Flagstaff International amended its Nov 2023 SPA to include a convertible promissory note component; Flagstaff has already made one $200,000 payment.
- The Series B Preferred Stock (part of the original $3M deal) is priced at $2.38 per share and ranks senior to common stock in liquidation.
- Alexander Capital L.P. acted as placement agent, receiving a 10% cash fee on gross proceeds.
- Proceeds are intended for working capital and general corporate purposes.
Neuraxis, Inc. announced a significant leadership transition involving the simultaneous resignation of its CFO and Audit Committee Chair, alongside the appointment of a new CFO who is also resigning from the Board.
🚩 Red Flags
- Simultaneous departure of the CFO and the Audit Committee Chair.
- The new CFO is transitioning directly from the Board to an executive role, which can sometimes indicate rapid restructuring or internal shifts.
- Unpaid cash fees ($20,000) owed to a departing director.
📋 Key Facts
- CFO John Seale resigned effective January 30, 2024.
- Timothy R. Henrichs resigned from the Board (Audit Committee Chair) effective February 2, 2024.
- Timothy R. Henrichs appointed as new CFO starting February 5, 2024, with an annual base salary of $330,000.
- The Company is issuing 100,000 shares of common stock to Mr. Henrichs as an inducement to join.
- Mr. Henrichs is owed approximately $20,000 in unpaid cash fees and $23,700 in stock for prior service as a non-employee director.